Enterprise Value
172.4B
Cash
4.095B
Avg Qtr Burn
N/A
Short % of Float
0.35%
Insider Ownership
0.06%
Institutional Own.
15.28%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Arexvy Details Viral infection, Respiratory syncytial virus, Vaccine | Approved Update | |
Arexvy Details Vaccine, Respiratory syncytial virus, Viral infection | Approved Quarterly sales | |
Ojjaara (Momelotinib) (JAK Inhibitor) Details Myelofibrosis | Approved Quarterly sales | |
Jesduvroq (Daprodustat) Details Chronic kidney disease | Approved Quarterly sales | |
Jemperli (dostarlimab) Details Cancer, Endometrial cancer | Approved Quarterly sales | |
MenABCWY vaccine 2nd gen Details Meningitis | PDUFA Approval decision | |
Jemperli (dostarlimab) Details Cancer, Endometrial cancer | PDUFA Approval decision | |
Bepirovirsen Details Hepatitis B vaccine | Phase 3 Data readout | |
Depemokimab Details Asthma | Phase 3 Data readout | |
BLU-5937 (P2X3 antagonist) Details Chronic cough | Phase 3 Data readout | |
Nucala Details Chronic obstructive pulmonary disease | Phase 3 Data readout | |
Zejula Details Cancer, Solid tumor/s, Lung cancer, Non-small cell lung carcinoma | Phase 3 Data readout | |
Cobolimab Details Lung cancer, Non-small cell lung carcinoma, Cancer, Solid tumor/s | Phase 3 Data readout | |
Depemokimab Details Chronic rhinosinusitis with nasal polyps | Phase 3 Data readout | |
Blenrep (belantamab mafodotin) + BorDex Details Multiple myeloma | Phase 3 Data readout | |
Linerixibat Details Primary biliary cholangitis | Phase 3 Data readout | |
Zejula Details Solid tumor/s, Platinum-resistant ovarian cancer, Ovarian cancer, Cancer | Phase 3 Data readout | |
Gepotidacin Details Prevention of gonorrhea | Phase 3 Update |